SIBN vs GMED

For growth investors, SI-BONE, Inc.

(SIBN) is the stronger pick with 20. 2% revenue growth year-over-year, versus 16. 7% for Globus Medical, Inc. (GMED). Globus Medical, Inc. (GMED) offers the better valuation at 21. 7x trailing P/E (19. 0x forward), making it the more compelling value choice. Analysts rate SI-BONE, Inc. (SIBN) a "Buy" — based on 9 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Globus Medical, Inc.

(GMED) delivered a total return of +16. 1%, compared to -60. 5% for SI-BONE, Inc. (SIBN). Over 10 years, the gap is even starker: GMED returned +264. 4% versus SIBN's -35. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), SI-BONE, Inc.

(SIBN) is the lower-risk stock at 1. 12β versus Globus Medical, Inc. 's 1. 29β — meaning GMED is approximately 15% more volatile than SIBN relative to the S&P 500. On balance sheet safety, SI-BONE, Inc. (SIBN) carries a lower debt/equity ratio of 1% versus 3% for Globus Medical, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), SI-BONE, Inc.

(SIBN) is pulling ahead at 20. 2% versus 16. 7% for Globus Medical, Inc. (GMED). On earnings-per-share growth, the picture is similar: Globus Medical, Inc. grew EPS 422. 7% year-over-year, compared to 41. 3% for SI-BONE, Inc.. Over a 3-year CAGR, GMED leads at 42. 2% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Globus Medical, Inc.

(GMED) is the more profitable company, earning 18. 3% net margin versus -9. 4% for SI-BONE, Inc. — meaning it keeps 18. 3% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: GMED leads at 16. 3% versus -11. 1% for SIBN. At the gross margin level — before operating expenses — SIBN leads at 79. 6%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for SIBN: 95.

0% to $25. 25.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Globus Medical, Inc.

(GMED) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 29), +264. 4% 10Y return). Both have compounded well over 10 years (GMED: +264. 4%, SIBN: -35. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.